Therapeutic Apheresis in Metabolic Syndrome
- PMID: 30369968
- PMCID: PMC6174637
- DOI: 10.2174/1871522218666180608114536
Therapeutic Apheresis in Metabolic Syndrome
Abstract
Background: The metabolic syndrome unites three pathologies of the person - obesity, arterial hypertension and diabetes. In recent years the progressing of such distribution covering from 2.5% to 3.8% of the population with increase twice each 10-15 years is noted. Even at maintenance of level of sugar at diabetes accumulation of the secondary metabolites breaking small vessels isn't excluded. At the same time many life-endangering complications develop.
Objective: To identify the possibilities of plasmapheresis in the prevention and treatment of complications of metabolic syndrome.
Method: Analysis of the world literature data on complications of metabolic syndrome and methods of their treatment.
Results: At metabolic syndrome the frequency of strokes and myocardial infarctions there is twice more often than in population. For 5-9 years the general life expectancy decreases. Disorders of microcirculation at diabetes lead to a retinopathy with total loss of sight, a nephropathy from the outcome in a renal failure, to polyneuropathy and diabetic foot syndrome with high risk of high level amputations of the lower extremities. At the same time medicamentous therapy is not able to prevent such complications and almost only way of removal of these pathological metabolites is therapeutic apheresis, mainly the plasmapheresis. Data from our own studies confirm the effectiveness of such tactics.
Conclusion: Plasmapheresis has to be applied not only to the correction of already critical conditions, but also to their prevention.
Keywords: Metabolic syndrome; diabetes; diabetic foot; diabetic nephropaty; plasma-pheresis; retinopathy.
Figures
Similar articles
-
[Chronic complications and risk factors in patients with type 1 diabetes mellitus--retrospective analysis].Przegl Lek. 2003;60(12):773-7. Przegl Lek. 2003. PMID: 15058014 Polish.
-
Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy.Cochrane Database Syst Rev. 2023 Feb 22;2(2):CD013775. doi: 10.1002/14651858.CD013775.pub2. Cochrane Database Syst Rev. 2023. PMID: 36815723 Free PMC article. Review.
-
[Prevention of diabetic foot].Acta Med Croatica. 2013 Oct;67 Suppl 1:35-44. Acta Med Croatica. 2013. PMID: 24371974 Croatian.
-
Approaches to prevention of cardiovascular complications and events in diabetes mellitus.Drugs. 2007;67(7):997-1026. doi: 10.2165/00003495-200767070-00005. Drugs. 2007. PMID: 17488145 Review.
-
Metabolic Syndrome in Type 2 Diabetes Mellitus Patients: Prevalence, Risk Factors, and Associated Microvascular Complications.Cureus. 2023 May 16;15(5):e39076. doi: 10.7759/cureus.39076. eCollection 2023 May. Cureus. 2023. PMID: 37323312 Free PMC article.
Cited by
-
Advanced glycation end products and adipocytokines and oxidative stress in placental tissues of pregnant women with gestational diabetes mellitus.Exp Ther Med. 2019 Jul;18(1):685-691. doi: 10.3892/etm.2019.7623. Epub 2019 May 28. Exp Ther Med. 2019. PMID: 31281448 Free PMC article.
References
-
- Clarson C.L., Mahmud F.H., Baker J.E., Clark H.E., McKay W.M., Schauteet V.D., Hill D.J. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine. 2009;36(1):141–146. - PubMed
-
- Goh V.H.H., Hart W.G. Excess fat in the abdomen but not general obesity is associated with poorer metabolic and cardiovascular health in premenopausal and postmenopausal Asian women. Maturitas. 2018;107:33–38. - PubMed
LinkOut - more resources
Full Text Sources